Nexalin Technology (Nasdaq: NXL) has been awarded a key patent relating to the company’s non-invasive, frequency-based deep brain stimulation device by the United States Patent…
January 29, 2024
Shares in Palisade Bio (Nasdaq: PALI) rose by more than 100% in intraday trading on Monday after the company announced positive preclinical data from a…
January 26, 2024
60 Degrees Pharmaceuticals to Initiate Clinical Trial for Tick-Borne Disease Treatment
60 Degrees Pharmaceuticals (Nasdaq: SXTP) will move forward with a pivotal clinical study of tafenoquine in hospitalized babesiosis patients in the U.S. following a Type…
January 25, 2024
Incannex Completes Dosing in Psilocybin Anxiety Study
Incannex Healthcare (Nasdaq: IXHL) has completed dosing of 72 participants in a Phase 2 clinical study evaluating a psilocybin treatment program for patients with generalized…
January 25, 2024
AIM ImmunoTech Enrolls First Patient in Pancreatic Cancer Study
AIM ImmunoTech (Nasdaq: AIM) has enrolled the first subject in a Phase 1b/2 clinical trial combining AIM’s Ampligen® (rintatolimod) with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor…
Cybin Inc. (NYSE American: CYBN) has been granted FDA clearance for its investigational new drug (IND) application for CYB004, its proprietary deuterated dimethyltryptamine (DMT) molecule…
Shares in Sagimet Biosciences Inc. (Nasdaq: SGMT) soared 170% on Monday after the biopharmaceutical company announced positive topline results from its Phase 2b FASCINATE-2 clinical…
Clinical stage biotechnology company, Vaxart, Inc. (Nasdaq: VXRT), has been awarded $9.27 million by the United States Biomedical Advanced Research and Development Authority (BARDA) to…
January 18, 2024
Lisata Treats First Patient in Glioblastoma Clinical Trial
Lisata Therapeutics (Nasdaq: LSTA) has treated the first patient in a Phase 2a trial evaluating LSTA1 in patients with newly diagnosed glioblastoma multiforme (GBM). The…
January 17, 2024
Bullfrog AI Collaboration is ‘First Step Towards Personalized Medicine in Psychiatry’; Shares Soar 30%
Bullfrog AI (Nasdaq: BRFG) shares are up more than 32% in morning trading on Wednesday after the company announced a collaboration with the Lieber Institute…
January 17, 2024
Lexaria to Undertake Extensive GLP-1 Study Program to Support Commercial Discussions
Lexaria Bioscience (Nasdaq: LEXX) has announced it will initiate an extensive glucagon-like peptide-1 (GLP-1) study program in 2024 to support prospective commercial partnering with the…
Vaxart, Inc. (Nasdaq: VXRT) announced today that it had entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615…